Table of Contents
Overview
New York, NY – July 29, 2025: The Global Minimal Residual Disease (MRD) market is projected to grow from USD 2.2 billion in 2024 to USD 6.5 billion by 2034, expanding at a CAGR of 11.4%. One major driver of this growth is the increasing number of cancer cases worldwide. As more patients undergo treatment, the need for post-treatment monitoring has become critical. MRD testing helps detect even the smallest traces of cancer cells that standard imaging might miss. This supports better long-term management and earlier intervention for relapse.
Advanced diagnostic tools are making MRD testing more effective. Technologies like digital PCR, liquid biopsy, and next-generation sequencing can now identify cancer at very low levels. These innovations improve both accuracy and speed, allowing doctors to adjust treatments in real time. Faster and more precise testing is encouraging wider adoption of MRD in both research labs and clinical settings, making it a key tool in modern cancer diagnostics.
MRD testing is also playing a vital role in the shift toward personalized medicine. Oncologists use MRD results to understand how each patient responds to treatment. If any residual cancer is detected, treatment plans can be tailored or changed. This personalized approach improves outcomes and reduces unnecessary therapies. Healthcare providers, research institutions, and public systems are increasingly supporting this model to boost recovery rates and reduce treatment side effects.
Governments and health organizations are including MRD testing in national guidelines, especially for blood cancers like leukemia and lymphoma. It’s also used in clinical trials to assess the effectiveness of new drugs. As more evidence proves its benefits, hospitals are adopting MRD as a standard tool for monitoring cancer. Its role in guiding treatment decisions makes it essential in routine oncology care, particularly in high-risk patients.
Support from public health systems is further fueling growth. Several countries are integrating MRD testing into their public healthcare services. Funding and training programs are being developed to make these tools more accessible. At the same time, developing regions in Asia and South America are investing in diagnostic infrastructure. As access to healthcare improves in these areas, MRD testing is becoming more common, helping expand the global reach of cancer monitoring and care.
Key Takeaways
- In 2024, the minimal residual disease market generated around US$ 2.2 billion, with expectations to reach US$ 6.5 billion by 2034.
- The market is growing steadily at a compound annual growth rate (CAGR) of 11.4% over the forecast period from 2025 to 2034.
- Among product types, flow cytometry led the market in 2024, accounting for the largest share of 55.2% due to its accuracy and speed.
- Next-generation sequencing (NGS) and PCR are also gaining traction, but flow cytometry remains the most widely adopted technology in this space.
- In terms of application, hematological malignancies dominated with a 72.3% share, largely due to their suitability for MRD monitoring.
- Solid tumors represent a smaller portion of the market but are expected to grow as MRD applications expand beyond blood-related cancers.
- Hospitals and specialty clinics emerged as top end users, securing a dominant 59.4% revenue share in the minimal residual disease market.
- Academic institutions and diagnostic labs also contribute to market growth, though hospitals continue to be the main centers for MRD testing.
- Regionally, North America held the leading position with a 42.5% market share, driven by advanced healthcare systems and high cancer prevalence.
- The U.S. in particular contributes significantly to North America’s leadership, thanks to strong investments in cancer diagnostics and research.
Segmentation Analysis
Product Type Analysis
In 2024, the flow cytometry segment led the minimal residual disease (MRD) market with a 55.2% share. This is due to its high accuracy and ability to analyze small traces of residual disease in blood cancers. Flow cytometry is especially effective in leukemia and lymphoma cases. Its quick turnaround and high sensitivity make it a preferred choice for MRD testing. Technological improvements like multi-parametric analysis and automation continue to strengthen its diagnostic role. These advancements are expected to drive further growth as clinicians seek precise monitoring tools.
Technology Analysis
Hematological malignancies accounted for a 72.3% share in the MRD technology segment in 2024. The increasing need for accurate MRD detection in cancers like leukemia, lymphoma, and myeloma is fueling this trend. Technologies such as flow cytometry and next-generation sequencing (NGS) are improving detection sensitivity. Their use helps doctors tailor treatment plans and monitor relapses more effectively. As these cancers become more common, MRD testing in this area will likely expand. Personalized medicine and early detection strategies are also boosting demand in this technology segment.
End-User Analysis
Hospitals and specialty clinics held a 59.4% revenue share in 2024, showing strong growth in the MRD market. These facilities are central to diagnosing and managing MRD, especially in blood cancers. Their access to molecular diagnostics and personalized treatment makes them key users of MRD tools. Increased investment in technologies like NGS and flow cytometry is enhancing their testing capabilities. The growth of cancer-focused outpatient clinics also supports market expansion. These centers offer convenient, specialized care, which boosts the adoption of MRD diagnostics across healthcare systems.
Key Market Segments
By Product Type
- Flow Cytometry
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Others
By Technology
- Hematological Malignancy
- Lymphoma
- Leukemia
- Solid Tumors
By End-user
- Hospitals & Specialty Clinics
- Academic & Research Institutes
- Diagnostic Laboratories
- Others
Regional Analysis
North America Leads the Minimal Residual Disease Market
North America held a 42.5% revenue share in the MRD market, driven by strong cancer detection efforts and advanced diagnostics. The U.S. saw 1.9 million new cancer cases in 2022, according to the American Cancer Society. This raised demand for early detection methods like MRD testing. In 2023, the NIH raised cancer research funding by 15%, reaching US$7.3 billion. The FDA approved several MRD assays, including ClonoSEQ, which saw a 25% increase in use. Over 60% of U.S. oncology clinics adopted MRD testing by 2024, up from 40% in 2022.
Asia Pacific to Witness the Fastest MRD Market Growth
Asia Pacific is expected to grow at the highest CAGR due to more healthcare spending and rising cancer awareness. The WHO reported a 12% rise in cancer cases from 2022 to 2024 in this region. China and India made up nearly 50% of the cancer burden. China raised its cancer research budget by 20% in 2023. Japan approved MRD testing in 2023, with a 30% rise in adoption. India saw a 40% increase in MRD services. South Korea approved three new MRD kits in 2024, boosting diagnostic access.
Key Players Analysis
Key players in the Minimal Residual Disease (MRD) market are focusing on innovation, partnerships, and portfolio expansion. They are investing heavily in research and development to improve the sensitivity and accuracy of diagnostic tools. This helps detect residual cancer cells at much lower levels. Many companies are collaborating with academic institutions and biotech firms. These partnerships help accelerate product development and strengthen market presence. Expansion into emerging markets is also a priority, as companies aim to tap into growing healthcare investments and reach a broader patient base.
Continuous regulatory approvals and innovations in liquid biopsy technologies are supporting the widespread use of MRD detection. Among the leading players, Bio-Techne Corporation stands out. Headquartered in Minneapolis, Minnesota, the company develops high-quality biotech tools for research and clinical diagnostics. It offers a wide range of cancer detection solutions, including MRD testing platforms and advanced molecular assays. Bio-Techne aims to enhance diagnostic precision and patient care. Its global presence is growing through strategic acquisitions and partnerships in the oncology sector.
Top Key Players in the Minimal Residual Disease Market
- QIAGEN
- Personalis
- Invitae
- Guardant Health
- GRAIL, LLC
- FOUNDATION MEDICINE, INC
- Hoffmann-La Roche Ltd
- Exact Sciences Corporation
Emerging Trends
Liquid Biopsies Are Gaining Popularity
Traditional Minimal Residual Disease tests needed bone marrow or tissue biopsies. These procedures were invasive and painful for patients. Today, liquid biopsies are changing that. These are blood-based tests that find cancer cells still in the body after treatment. They detect tiny traces of cancer DNA in the bloodstream. The process is much easier on the patient. It can also be done more frequently to monitor changes over time. This makes it easier for doctors to catch early signs of relapse. Liquid biopsies are becoming a more practical and patient-friendly tool in cancer care.
MRD Use Is Growing Beyond Blood Cancers
MRD testing started with blood cancers like leukemia and lymphoma. Now, it’s also being used in solid tumors. These include colon, lung, breast, and bladder cancers. Doctors use MRD results to guide follow-up treatments. It helps them decide if chemotherapy or other therapy is still needed. In some cases, it prevents unnecessary treatments. In others, it signals the need for stronger follow-up care. This wider use is making MRD a key part of cancer monitoring across many types of cancer. It also gives patients more personalized care after surgery or treatment.
Personalized MRD Monitoring Is Advancing
Minimal Residual Disease tests are becoming more personalized. Some tests are now based on a patient’s unique tumor profile. Doctors first analyze the patient’s tumor DNA. Then they build a test that can find even the smallest leftover cancer cells. This customized approach improves sensitivity. It increases the chances of catching the disease early if it returns. Personalized MRD testing helps avoid one-size-fits-all treatment. Instead, care is based on each person’s needs. This trend is making MRD tests more precise and useful in real-world treatment plans.
Clinical Trials Are Using MRD More Often
MRD is now a key part of many cancer clinical trials. Researchers use it to check how well treatments are working. If cancer cells are still present after treatment, doctors can adjust the therapy. This might mean increasing or stopping treatment depending on the result. MRD is helping guide more flexible and effective care plans. It also helps identify which patients are at higher risk of relapse. Because of this, MRD testing is becoming a standard part of trial design. It’s shaping how new cancer therapies are tested and approved.
Use Cases
Tracking How Well Treatment Works
Minimal Residual Disease testing helps doctors see if a treatment, like chemotherapy or targeted therapy, is working. If MRD turns negative during treatment, it’s a sign that the therapy is effective. If MRD stays positive, the cancer might still be active. In that case, the treatment plan may need to change earlier than usual. This real-time feedback helps avoid delays in care. It also ensures that patients get the most effective therapies as soon as possible. MRD testing gives doctors better control over treatment outcomes and helps tailor care to each patient’s needs.
Predicting Cancer Relapse Early
Minimal Residual Disease is a useful tool for predicting if cancer might return. In many cases, it can detect signs of relapse even before symptoms appear or imaging tests show anything. This early warning allows doctors to act fast. They can adjust treatments or start new ones before the disease grows. This helps improve long-term survival chances. By finding recurrence earlier, MRD testing gives doctors and patients more time to respond. It also helps reduce the fear of sudden relapse, offering a proactive way to manage care during remission.
Deciding on Stem Cell Transplants or More Therapy
In blood cancers like leukemia and multiple myeloma, MRD helps guide big treatment decisions. If MRD is negative, the patient may not need more aggressive options like a stem cell transplant. If MRD is positive, doctors may recommend closer follow-up or stronger treatments. This personalized approach prevents unnecessary procedures. It also ensures that patients who need intensive care receive it at the right time. MRD testing gives a clearer understanding of how much cancer is left and helps make smarter decisions about what to do next.
Routine Monitoring After Treatment Ends
Even after treatment is over, MRD tests can continue to play a role. Doctors often use them during regular check-ups to look for any signs of cancer returning. This ongoing surveillance is more sensitive than traditional lab tests or scans. If MRD becomes positive again, action can be taken quickly. In many cases, treatment can start before the cancer spreads or symptoms appear. Regular MRD testing gives both doctors and patients peace of mind. It allows for early interventions and helps keep the disease under control for the long term.
Conclusion
Minimal Residual Disease (MRD) testing is becoming an essential part of modern cancer care. It helps doctors find small traces of cancer that might remain after treatment. This leads to better treatment decisions and improves patient outcomes. MRD tests are now easier to use, thanks to new tools like liquid biopsies and personalized assays. These advancements support early detection, more accurate monitoring, and tailored therapies. MRD is also being used in more types of cancer, including solid tumors. As healthcare systems and research continue to evolve, MRD will play a growing role in guiding treatment, reducing relapse, and supporting long-term recovery for cancer patients around the world.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
